Bengaluru: Indegene Limited has become the first industry partner of the Indo-UK Life Science Corridor, a joint initiative of Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London aimed at connecting the life sciences research and innovation ecosystems of India and the UK.
Under the partnership, Indegene will work with the two institutions to identify industry challenges, develop entrepreneurship programmes and facilitate startup exchanges between the countries.
The initial areas of collaboration include antimicrobial resistance, diagnostics, digital health, agritech, brain science and mental health.
The announcement was made on November 19 at the C-CAMP-Imperial roundtable on International Partnerships for AI Discovery and Innovation, held during the Bengaluru Tech Summit 2026.
Indegene Limited’s participation brings an industry partner into an initiative launched earlier this year to facilitate cross-border research collaboration, talent exchange and the development of life sciences innovations.
“Welcoming Indegene Limited as the first industry partner of the Indo-UK Life Sciences Innovation Corridor is an important moment for this partnership.
When we launched the initiative with C-CAMP earlier this year, we wanted to create a platform where research, talent and industry could come together to accelerate new technologies and solve shared global challenges.
Indegene Limited’s expertise in life sciences make them an ideal first partner as we strengthen India-UK links and grow our network of industry collaborators,” said Amanda Wolthuizen, Vice-President (Strategy), Imperial College London.
Dr Saurabh Jain, Vice President – Global Delivery Centers, CSR, and Advocacy, Indegene, said: “The next decade of life sciences innovation will be defined by how well we connect science, talent, and industry across borders.
This Corridor brings together the strengths of India and the UK, giving promising ideas a clearer path from discovery to real-world impact.
The partnership reflects our continued commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale.”
Five-Year India-UK Life Sciences Partnership
C-CAMP and Imperial College London formally launched the Indo-UK Life Sciences Innovation Corridor through a five-year memorandum of understanding signed on May 6, 2026.
The agreement provides for two-way collaboration, allowing UK-based research teams to explore deployment opportunities in India and Indian innovators to assess potential markets in the UK and Europe.
The institutions also outlined plans to explore joint fundraising and partnerships to support the initiative.
The Corridor operates through Imperial Global India, an initiative launched by Imperial College London in 2025 to strengthen its research and technology collaborations with Indian institutions and industry.
C-CAMP CEO Dr Taslimarif Saiyed said the initiative was designed to connect the complementary innovation ecosystems of the two countries.
“Global health challenges cannot be solved in isolation”, he said. “This understanding was central to our vision for the Indo-UK Life Science Corridor, which connects the complementary innovation ecosystems of Imperial College London and C-CAMP to enable cross-border problem-solving.
Exposure to both ecosystems will produce smarter, more scalable, and more accessible innovations relevant to both populations.”
Indegene Limited’s Earlier Collaboration with C-CAMP
The partnership also builds on an existing relationship between Indegene Limited and C-CAMP established in March 2024.
The organisations had entered into a multi-year collaboration to support early-stage life sciences startups through financial assistance, specialised mentorship and digital services.
The programme aimed to help C-CAMP nurture at least five to seven deep-science startups and accelerate their technology development and commercialisation.
C-CAMP has supported more than 700 startups over the past decade. Its portfolio companies have collectively raised over $720 million and have an estimated cumulative valuation of approximately $2.7 billion.
More than 420 life sciences products from its ecosystem have reached the market, while its startups have filed over 1,000 patents.
Indegene Limited Reports 39.5% Revenue Growth in Q2 FY27
Indegene Limited reported revenue from operations of ₹1,122.3 crore ($117.5 million) for the September quarter of FY27, marking a 39.5% year-on-year increase.
EBITDA rose 32% to ₹187.3 crore, with a margin of 16.7%, while profit after tax increased 10% to ₹112.3 crore.
The company reported 107 active clients during the quarter. Its customer base included 59 clients generating more than $1 million in annual revenue, of which 13 contributed over $10 million each.
Indegene describes itself as an AI-native operating partner for the life sciences industry, with experience serving leading global biopharmaceutical companies.




